Current treatment of chronic HBV infection: An Asian-Pacific perspective

被引：1
作者：
Liaw Y.-F. [1 ]
Chien R.-N. [1 ]
机构：
[1] Chang Gung Memorial Hospital and University, Taipei
来源：
Current Hepatitis Reports | 2009年 / 8卷 / 4期
关键词：
Chronic Hepatitis; Entecavir; HBeAg Seroconversion; Adefovir Dipivoxil; HBeAg Seroconversion Rate;
D O I：
10.1007/s11901-009-0022-x
中图分类号：
学科分类号：
摘要：
Chronic hepatitis B virus (HBV) infection is a major global health problem with potential adverse sequelae including liver cirrhosis and hepatocellular carcinoma. Of more than 350 million chronic HBV carriers, 75% reside in the Asian-Pacific region, where most countries have low-income economies. Better understanding of the natural history and immunopathogenesis of chronic HBV infection and the invention of powerful antiviral agents have improved the therapeutic strategy. Guidelines issued by major liver associations are basically similar. However, each country in the Asian-Pacific region has specific problems. Because cost is a main concern, drugs with low genetic barrier to resistance are still widely used in these countries. Modifications needed to accommodate specific situations and problems include more stringent indications for drug therapy, starting therapy with the least expensive drug, and defining stopping rules even for hepatitis B e antigen-negative patients. © 2009 Springer Science+Business Media, LLC.
引用
收藏
页码：154 / 160
页数：6
相关论文
共 55 条
  • [41] Lai C.-L., Gane E., Liaw Y.-F., Hsu C.-W., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Rasenack J., Bzowej N., Naoumov N.V., Di Bisceglie A.M., Zeuzem S., Moon Y.M., Goodman Z., Chao G., Constance B.F., Brown N.A., Telbivudine versus lamivudine in patients with chronic hepatitis B, New England Journal of Medicine, 357, 25, pp. 2576-2588, (2007)
  • [42] Tassopoulos N.C., Volpes R., Pastore G., Et al., Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B, Hepatology, 29, pp. 889-896, (1999)
  • [43] Chien R.N., Liaw Y.F., Short term lamivudine therapy in active HBeAg-negative chronic hepatitis B patients in Taiwan, Antivir Ther, 11, pp. 947-952, (2006)
  • [44] Liaw Y.-F., Chien R.-N., Yeh C.-T., Tsai S.-L., Chu C.-M., Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy, Hepatology, 30, 2, pp. 567-572, (1999)
  • [45] Liaw Y.-F., Sung J.J.Y., Chow W.C., Farrell G., Lee C.-Z., Yuen H., Tanwandee T., Tao Q.-M., Shue K., Keene O.N., Dixon J.S., Gray D.F., Sabbat J., Lamivudine for patients with chronic hepatitis B and advanced liver disease, New England Journal of Medicine, 351, 15, (2004)
  • [46] Di Marco V., Marzano A., Lampertico P., Andreone P., Santantonio T., Almasio P.L., Rizzetto M., Craxi A., Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine, Hepatology, 40, 4, pp. 883-891, (2004)
  • [47] Papatheodoridis G.V., Dimou E., Dimakopoulos K., Manolakopoulos S., Rapti I., Kitis G., Tzourmakliotis D., Manesis E., Hadziyannis S.J., Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine, Hepatology, 42, 1, pp. 121-129, (2005)
  • [48] Chien R.N., Liaw Y.F., Nucleos(t)ide analogues for hepatitis B virus: Strategies for long-term success, Best Pract Res Clin Gastroenterol, 22, pp. 1081-1092, (2008)
  • [49] Lampertico P., Vigano M., Manenti E., Iavarone M., Sablon E., Colombo M., Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients, Gastroenterology, 133, 5, pp. 1445-1451, (2007)
  • [50] Liaw Y.F., On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: Now and future, Antivir Ther, 14, pp. 13-22, (2009)
123456